Crystal structure of a genotype 1a/3a chimeric HCV NS3/4A protease in complex with danoprevir

(2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8 ,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.

The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.

HMASMKKKGSVVIVGRINLSGDTAYAQQTRGEEGCQETSQTGRDKNQVEGEVQIVSTATQTFLATSINGVLWTVYHGAGT
RTIASPKGPVTQMYTNVDKDLVGWQAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSTGSLLSPRPLSYLKGSSGG
PLLCPAGHAVGIFRAAVSTRGVAKAVQFIPVESLETTM

100mM MES buffer pH 6.5, 4% (w/v) ammonium sulfate, 20-26% PEG 3350

National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

chain 'A' and (resid 1000 through 1032 )

chain 'A' and (resid 1033 through 1091 )

chain 'A' and (resid 1092 through 1118 )

chain 'A' and (resid 1119 through 1134 )

chain 'A' and (resid 1135 through 1179 )

danoprevir, drug resistance, HCV protease inhibitor, genotype 3, HYDROLASE, HYDROLASE-HYDROLASE Inhibitor complex

TAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDKDLV
GWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGV
AKAVDFIPVESLETTM